Elevance Health vs Regeneron Pharmaceuticals
Elevance Health (ELV), health care, and Regeneron Pharmaceuticals (REGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Regeneron Pharmaceuticals is worth $99.2B on the stock market and Elevance Health $94.7B: Regeneron Pharmaceuticals is valued at 5% more. Elevance Health trades at 18.6 times earnings and Regeneron Pharmaceuticals at 21.2; operating margins in their latest fiscal years were 3.62% and 24.9%. Over the past year Elevance Health's share price has moved +37.5% and Regeneron Pharmaceuticals's +31.3%.
Key facts
- Elevance Health market value
- $94.7B
- Regeneron Pharmaceuticals market value
- $99.2B
- Elevance Health P/E
- 18.6
- Regeneron Pharmaceuticals P/E
- 21.2
- Elevance Health revenue
- $199.1BFY to 2025-12-31
- Regeneron Pharmaceuticals revenue
- $14.3BFY to 2025-12-31
- Superinvestors holding both
- 3
Market values as of .
| Measure | Elevance Health | Regeneron Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $94.7Blower | $99.2Bhigher |
| Revenue | $199.1Bhigher | $14.3Blower |
| Earnings | $5.7Bhigher | $4.5Blower |
| Employees | 96,129higher | 15,410lower |
| Total assets | $121.5Bhigher | $40.6Blower |
| Valuation | ||
| P/E | 18.6lower | 21.2higher |
| P/S | 0.5lower | 6.9higher |
| P/B | 2.1lower | 2.9higher |
| Dividend yield | 1.54%higher | 0.39%lower |
| Profitability | ||
| Operating margin | 3.62%lower | 24.9%higher |
| Balance sheet | ||
| Net assets | $43.9Bhigher | $31.3Blower |
| Total liabilities | $77.5Bhigher | $9.3Blower |
| Total debt | $32Bhigher | $2Blower |
| Cash on hand | $9.5Bhigher | $3.1Blower |
| Price change | ||
| Today | -1.76%lower | +0.66%higher |
| 1 year | +37.5%higher | +31.3%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (3)
- Harry Burn2.0% / 3.0%
- Jeremy Grantham (co-founder)1.4% / 0.1%
- Jim Simons (1938–2024)0.2% / 0.3%
Elevance Health only (16)
- Seth Klarman9.8%
- Sequoia Fund team6.2%
- Glenn Greenberg5.2%
- Matthew McLennan2.6%
- Bill Nygren2.5%
- Lew Sanders2.2%
- C.T. Fitzpatrick1.7%
- Stephen Yacktman1.6%
- Anthony Bozza1.2%
- Diamond Hill team0.9%
- Larry Robbins0.5%
- Baillie Gifford team0.4%
- Richard Pzena0.3%
- Tweedy, Browne team0.2%
- Ken Griffin0.2%
- Israel Englander0.2%
Regeneron Pharmaceuticals only (7)
Percentages are each holding's share of that investor's reported portfolio (under "Both": Elevance Health / Regeneron Pharmaceuticals). Who owns ELV · Who owns REGN
More on Elevance Health
Further comparisons
Elevance Health against its closest peers
Regeneron Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, Elevance Health or Regeneron Pharmaceuticals?
By market value, Regeneron Pharmaceuticals is the larger: $99.2B against $94.7B for Elevance Health. By revenue in its latest fiscal year, Elevance Health is the larger: $199.1B against $14.3B for Regeneron Pharmaceuticals.
Which has the higher P/E ratio?
Regeneron Pharmaceuticals: 21.2, against 18.6 for Elevance Health. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Regeneron Pharmaceuticals: 24.9%, against 3.62% for Elevance Health. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Elevance Health: 1.54%, against 0.39% for Regeneron Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Elevance Health: $32B, against $2B for Regeneron Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Elevance Health and Regeneron Pharmaceuticals?
In their latest 13F filings, Harry Burn, Jeremy Grantham (co-founder) and Jim Simons (1938–2024) hold both.
Cite this page
Funkfolio, “Elevance Health vs Regeneron Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/elv-vs-regn
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.